Each shareholder of the Framingham, Mass.-based company will receive $58 without interest against each outstanding common stock of the company.
According to the article, the acquisition will improve Medtronic’s position in the heart failure technology space. HeartWare produces miniaturized versions of ventricular assist devices, or implantable heart pumps, which has become a popular device among cardiologists.
The buyout won’t affect Medtronic’s fiscal year 2017 operating results, but analysts speculate the merger will also help the company to deliver on its FY 17 revenue growth outlook.
More articles on supply chain:
Medical device industry agrees to FDA’s device user fees to raise regulatory funding
3 things to know about the US’ potential flu vaccination shortage
FDA: Drug companies abuse citizen petitions to block generic competition
